With breast cancer readout for ADC, Dutch biotech Byondis aims for submission, seeks deal to finance pipeline

Byondis hopes a pivotal readout for its ADC to treat breast cancer will result in a transformational partnership that will allow the Dutch biotech to develop a pipeline with up to four more clinical candidates by 2023.

Spun out of parent company Synthon B.V. following its acquisition by BC Partners in 2019, Byondis B.V. is advancing a pipeline based in part on antibody-drug conjugate linker technology it gained through the 2011 acquisition of Syntarga B.V. Synthon had already created a biosimilar version of Herceptin trastuzumab; by adding a duocarmycin payload using the linker, the company constructed [vic-]trastuzumab duocarmazine (SYD985), CEO Marco Timmers told BioCentury...